Zhou Mo, Abid Muhammad, Cao Shinuo, Zhu Shanyuan
Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225306, China.
Viral Oncogenesis Group, The Pirbright Institute, Ash Road Pirbright, Woking, Surrey GU24 0NF, UK.
Viruses. 2022 Aug 11;14(8):1753. doi: 10.3390/v14081753.
Pseudorabies virus (PRV) is the causative agent of pseudorabies (PR), infecting most mammals and some birds. It has been prevalent around the world and caused huge economic losses to the swine industry since its discovery. At present, the prevention of PRV is mainly through vaccination; there are few specific antivirals against PRV, but it is possible to treat PRV infection effectively with drugs. In recent years, some drugs have been reported to treat PR; however, the variety of anti-pseudorabies drugs is limited, and the underlying mechanism of the antiviral effect of some drugs is unclear. Therefore, it is necessary to explore new drug targets for PRV and develop economic and efficient drug resources for prevention and control of PRV. This review will focus on the research progress in drugs and drug targets against PRV in recent years, and discuss the future research prospects of anti-PRV drugs.
伪狂犬病病毒（PRV）是伪狂犬病（PR）的病原体，可感染大多数哺乳动物和一些鸟类。自发现以来，它已在全球范围内流行，给养猪业造成了巨大的经济损失。目前，PRV的预防主要通过疫苗接种；针对PRV的特异性抗病毒药物很少，但用药物有效治疗PRV感染是可能的。近年来，有报道称一些药物可治疗PR；然而，抗伪狂犬病药物的种类有限，一些药物抗病毒作用的潜在机制尚不清楚。因此，有必要探索PRV的新药物靶点，并开发经济高效的药物资源用于PRV的预防和控制。本文综述将聚焦近年来抗PRV药物及药物靶点的研究进展，并探讨抗PRV药物的未来研究前景。
